The Pharma Letter3h
AI in cancer care set to become big business
The AI in cancer care market is set to grow from $2.2 billion in 2024 to $6.3 billion by 2029, driven by advancements in drug ...
The Pharma Letter9h
Tarlatamab greenlighted by MHRA for small cell lung cancer
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Imdyllytra (tarlatamab) for the ...
The Pharma Letter11h
MRHA clears Winrevair for pulmonary arterial hypertension
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary ...
The Pharma Letter12h
Axsome Phase III program of AXS-05 in Alzheimer’s disease agitation
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...
The Pharma Letter13h
CARsgen steps forward in race for first solid tumor-targeting CAR T
CARsgen Therapeutics reports positive Phase II data for satri-cel in advanced gastric and GEJ cancers, meeting the primary ...
The Pharma Letter13h
BeiGene exercises option on DualityBio’s B7H4 ADC
China-based biotech Duality Biologics (DualityBio) yesterday revealed that Sino-American BeiGene has exercised its exclusive ...
The Pharma Letter14h
Lilly’s Zepbound holds potential to dominate obesity market, says analyst
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with ...
The Pharma Letter13h
BRIEF—TJ Bio seeks China nod for growth hormone therapy
TJ Bio has reportedly submitted a biologics license application (BLA) to China’s Center for Drug Evaluation for GX-H9 ...